TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a small, single-arm study, 16 breast cancer survivors who completed eight weeks of oxaloacetate treatment had improved scores on a measure of perceived cognitive function. The findings are preliminary: there was no control group, and a randomized placebo-controlled study is expected to begin enrollment before the end of 2026.
A small study of breast cancer survivors found that perceived cognitive function improved after eight weeks of taking oxaloacetate, a supplement involved in cellular energy production and glutamate regulation. All 16 participants who completed the study showed improvement on the main cognitive assessment, but the trial had no control group, so it cannot establish that oxaloacetate caused the change.
Researchers enrolled 18 breast cancer survivors who were one to five years beyond cancer treatment and had reported cognitive impairment. Participants took 500 milligrams of oxaloacetate twice daily for eight weeks; two did not complete the study. The main outcome was participants’ perceived cognitive change, measured with the FACT-Cog PCI assessment.
Among those who completed treatment, the group’s mean FACT-Cog PCI score rose from 29.1 at baseline to 55.5 after eight weeks. The researchers said the average moved from the impaired range into the normal range. Improvement was observed at four weeks and generally grew over the remaining four weeks. Neuropsychological testing also showed improvement in executive function and processing speed.
The report also described significant improvements in fatigue and physical functioning, with a trend toward better insomnia. Reported adverse effects included indigestion, bloating, constipation and diarrhea. The study authors characterized the treatment as generally well tolerated, while the small sample and short follow-up limit what can be concluded about safety and benefit.
A Potential Option for Persistent Cognitive Symptoms
Cancer-related cognitive impairment, often called “chemo brain” or “brain fog,” can affect memory, concentration and other thinking skills after cancer treatment. The study’s results matter because patients have few established medication options for these symptoms, which can affect daily activities and quality of life. The reported changes in fatigue and physical function may also be relevant to survivors dealing with multiple ongoing effects after treatment.
However, the findings do not show that oxaloacetate works better than no treatment or another approach. Without a comparison group, changes could reflect factors such as expectations, natural variation, or other changes during the study. A larger randomized trial is needed to determine whether the supplement itself improves symptoms and whether any benefit lasts.
oxaloacetate supplement 500 mg capsules
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Oxaloacetate
The cause of cancer-related cognitive impairment is not fully understood. The report notes that the condition has been studied extensively among breast cancer survivors and that some chemotherapy agents can cross the blood-brain barrier and have recognized neurotoxic effects. Cognitive symptoms are not limited to breast cancer, though; clinicians also see them in people treated for other cancers.
Oxaloacetate is a naturally occurring human metabolite involved in energy production inside cells. It also has a role in regulating glutamate, a neurotransmitter connected to cognitive function. Previous research, including a small randomized study involving people with long COVID symptoms, provided a rationale for testing oxaloacetate in survivors with diagnosed cognitive impairment. Those earlier findings do not establish that it is effective for cancer-related symptoms.
In this study, the investigators initially planned a two-step design, with a four-point improvement on the FACT-Cog PCI among the first nine participants set as a positive result. The preliminary analysis showed a 27-point improvement, according to the report. The authors then changed the design to complete the study with fewer participants and move more quickly toward a randomized trial. That early result should be interpreted in light of the study’s small size and lack of a placebo group.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”
— Patricia Ganz, MD, UCLA Health, in a press release
What the Small Trial Cannot Show
The study included only 18 participants, with 16 completing treatment, and had no placebo or untreated comparison group. It therefore cannot determine whether oxaloacetate caused the score changes, how the supplement compares with other care, or whether improvements would persist after treatment ended. The report also does not establish whether the results apply to people with other cancer types or to survivors with different levels of impairment.
Side effects were reported, but this study was too small and brief to characterize uncommon or longer-term risks. The available report does not provide enough detail to assess how the observed changes affected participants’ everyday functioning beyond the measured outcomes. Those questions require further study.
A Placebo-Controlled Trial Is Planned
A randomized, placebo-controlled phase II study is expected to begin enrolling participants before the end of 2026, according to the report. Comparing oxaloacetate with placebo should help researchers distinguish treatment effects from changes that can occur without the supplement.
Readers should look for details on the planned trial’s enrollment criteria, size, duration, outcome measures and safety monitoring as they become available. Until controlled results are reported, this preliminary finding supports further testing; it does not establish oxaloacetate as a treatment for cancer-related cognitive impairment.
Key Questions
What did the study find?
Among 16 breast cancer survivors who completed eight weeks of oxaloacetate, the average score on a measure of perceived cognitive function rose from 29.1 to 55.5. The study also reported improvements in fatigue and physical functioning.
Does this prove oxaloacetate treats chemo brain?
No. The study was small and had no control group, so it cannot show that oxaloacetate caused the improvements. A randomized placebo-controlled trial is needed to test whether the supplement has a treatment effect.
What dose did participants take?
Participants took 500 milligrams twice daily for eight weeks. This was the dose used in the study; the report does not establish a recommended dose for patients.
What side effects were reported?
Reported effects included indigestion, bloating, constipation and diarrhea. The study authors described the supplement as generally well tolerated, but the small number of participants and short follow-up cannot rule out less common or longer-term risks.
When will a larger study begin?
A randomized, placebo-controlled phase II study is expected to begin enrollment before the end of 2026, according to the report. Further details, including its size and schedule, were not provided in the supplied material.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
